Advance Hepatocellular Carcinoma (HCC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Advanced Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma most often occurs in people with chronic liver disease, such as cirrhosis caused by hepatitis B or C infection. Worldwide, liver cancer was the sixth most common cancer and the third leading cause of cancer death in 2020, with an estimated 905,677 new cases and 830,180 deaths. East Asia had the highest incidence at 17.9 per 100,000 population (26.9 males and 8.9 females), followed by Micronesia, North Africa, Southeast Asia, and Melanesia. Management of hepatocellular carcinoma (HCC) is best performed in a multidisciplinary setting. Patients should be cooperatively managed by hepatologists, transplant and hepatobiliary surgeons, medical oncologists, interventional radiologists, and palliative care specialists. Specifically, this is crucial to ensure that patients who are candidates for liver transplantation are referred in a timely manner, while their tumors are within the Milan criteria.

Description

Advanced Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. People with chronic liver diseases, such as cirrhosis brought on by hepatitis B or C infection, are most likely to develop hepatocellular carcinoma. It is third leading cause of cancer-related deaths each year and is an aggressive cancer. Treatment for patients with HCC is difficult because the tumor stage and any underlying liver conditions must be taken into account. The only treatments that can be used for a significant portion of HCC patients are systemic ones because they are diagnosed at advanced stages. HCC patients require complex management because both the stage of the tumor and any underlying liver conditions must be taken into account. Despite routine imaging, clinical, and biochemical surveillance, many cirrhotic patients already have advanced-stage HCC when they are first diagnosed. Diverse patient populations with various clinical conditions and radiological characteristics make up advanced stage HCC.

Advance Hepatocellular Carcinoma (HCC) (Epidemiology)

With an estimated 905,677 new cases and 830,180 fatalities worldwide in 2020, liver cancer was the sixth most prevalent cancer and the third leading cause of cancer death. East Asia, Micronesia, North Africa, Southeast Asia, and Melanesia were the regions with the lowest incidence, each with 17.9 cases per 100,000 people (26.9 men and 8.9 women). The lowest incidence rates were found in South America (4.4 per 100,000 people) and Central and South Asia (3.0 per 100,000 people). This contrasts with rates of 6.9 per 100,000 in North America and 5.6 per 100,000 in Western Europe. Overall, men are three times more likely than women to develop liver cancer.

Advance Hepatocellular Carcinoma (HCC)-Current Market Size & Forecast Trends

The market for advanced hepatocellular carcinoma (HCC) is projected to grow significantly, with an estimated value of approximately USD 8.2 billion in 2021 and expected to reach around USD 7.3 billion by 2027, reflecting a compound annual growth rate (CAGR) of 17.39% during this period. Key growth drivers include the rising incidence of liver cancer globally and the expanding adoption of immunotherapies (e.g., Nivolumab and Atezolizumab). Overall, the HCC market is positioned for substantial growth through 2035 as new treatments continue to emerge.

Hepatocellular carcinoma (HCC) treatment is best performed in a multidisciplinary setting. Patients should be managed in conjunction with a hepatologist, transplant and hepatobiliary surgeon, oncologist, interventional radiologist, and palliative care specialist. It is especially crucial to do this to guarantee that patients who qualify for liver transplantation are promptly referred when their tumors meet the Milan criteria. The only available treatments are liver transplantation and surgical resection, both of which have limited effectiveness. Hepatocellular carcinoma patients who qualify for transplants make up only about 5% of the total population. These patients have a higher than 75% 5-year survival rate, and tumor recurrence rates can reach 15% within 5 years. So, to prevent relapse, the patient should get a transplant or, if that's not possible, be treated with other therapies. These include radiofrequency ablation (RFA), resection, and the possibility of systemic sorafenib treatment (or regorafenib, nivolumab, lenvatinib, pembrolizumab, cabozantinib, or ramucirumab if sorafenib is ineffective). Aggressive surgical intervention is linked to the best result in patients who experience recurrence after excision or transplantation. HCC has a high mortality rate. Systemic therapy now has more options than it did five years ago. Since its introduction as the only systemic therapy for HCC in 2007, sorafenib was the first multikinase inhibitor to be offered as a treatment option. In the wake of sorafenib's success, another multikinase inhibitor, lenvatinib, has gained approval for use in clinical trials in the primary setting. In quick succession, additional multikinase inhibitors, including regorafenib, ramucirumab, and cabozantinib, have been approved as second-line medications. Additionally, immune checkpoint inhibitors (ICIs) are now frequently approved treatments for a variety of solid tumors, including HCC. Programmed cell death-1 (PD-1), its ligand PD-L1, and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) are the three targets of the most researched ICI to date. Advanced hepatocellular carcinoma has been successfully treated with these ICIs. Atezolizumab, an ICI that targets PD-L1, and bevacizumab have recently been approved as the first-line standard of care. As a second-line therapy for patients who are resistant to sorafenib, the combination of ICI with nivolumab and ipilimumab has also been approved.

Report Highlights

Advance Hepatocellular Carcinoma (HCC)- Current Market Trends

Advance Hepatocellular Carcinoma (HCC)- Current & Forecasted Cases across the G8 Countries

Advance Hepatocellular Carcinoma (HCC)- Market Opportunities and Sales Potential for Agents

Advance Hepatocellular Carcinoma (HCC)- Patient-based Market Forecast to 2035

Advance Hepatocellular Carcinoma (HCC)- Untapped Business Opportunities

Advance Hepatocellular Carcinoma (HCC)- Product Positioning Vis-a-vis Competitors' Products

Advance Hepatocellular Carcinoma (HCC)- KOLs Insight